Welcome to our dedicated page for Elutia SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Elutia’s filings can feel like untangling lab notes—clinical trial updates, device-tissue interaction data, and shifting FDA timelines are buried inside hundreds of pages. If you have ever searched for “Elutia SEC filings explained simply” or wondered how a single footnote can change the outlook for drug-eluting biomatrix sales, you are not alone.
Stock Titan solves this problem. Our AI parses every document the moment it hits EDGAR, turning dense text into clear takeaways. Need the Elutia quarterly earnings report 10-Q filing to spot Women’s Health revenue trends? We highlight them in seconds. Tracking Elutia insider trading Form 4 transactions? Real-time alerts flag each executive stock move, so you catch patterns before the market reacts.
All filing types are here—10-K, 10-Q, 8-K, S-1, and the proxy statement—each paired with concise, plain-language summaries:
- 10-K annual report: See R&D spend, segment margins, and risk factors in our “Elutia annual report 10-K simplified” view.
- Form 4 insider activity: Drill into “Elutia Form 4 insider transactions real-time” to gauge leadership confidence.
- 8-K material events: Follow trial results or distribution deals under “Elutia 8-K material events explained”.
- Proxy statement: Compare “Elutia proxy statement executive compensation” against peer med-tech firms.
Use cases span monitoring device-protection adoption, evaluating cardiovascular pipeline milestones, and verifying regulatory progress—all without wading through jargon. From “Elutia earnings report filing analysis” to “understanding Elutia SEC documents with AI,” Stock Titan gives you the context, numbers, and narrative you need to act confidently.
Form 4 overview: On 06/21/2025 Elutia Inc. (ELUT) filed a Form 4 detailing equity activity by President & CEO C. Randal Mills, who is also a director.
Transactions:
- 22,473 Class A shares were acquired through the vesting and settlement of an equal number of restricted stock units (RSUs) (Code “M”).
- 8,019 shares were withheld at $1.81 per share to satisfy tax obligations (Code “F”).
The net increase to the executive’s direct holdings is 14,454 shares.
Post-transaction ownership: Mills now directly owns 321,167 Class A shares. Table II shows 22,473 RSUs still outstanding, indicating additional shares may be delivered in future periods.
Award background: The underlying RSU grant was issued on 06/21/2022 for 89,893 units, vesting in four equal annual tranches beginning 06/21/2023. The current filing represents the second scheduled vesting installment.
No open-market purchases or sales occurred, and the form does not cite a Rule 10b5-1 plan. As such, the disclosure reflects a routine insider vesting event with limited immediate market impact for investors.
FAQ
What is the current stock price of Elutia (ELUT)?
What is the market cap of Elutia (ELUT)?
What is the primary focus of Elutia Inc?
Which business segments does Elutia Inc operate in?
How do Elutia Inc's products address unmet clinical needs?
What technological approach underpins Elutia Inc's product offerings?
How does Elutia Inc differentiate itself in the competitive regenerative medicine landscape?
What role does the Women's Health segment play for Elutia Inc?
How does the company ensure the quality of its biomatrix products?
Can you explain the importance of drug-eluting biomatrix technology in medical implants?
